Dr @andreafava presents their noninvasive biomarker panel that predicted the probability of histologically active LN. Panel outperformed UPCR, C3, C4 & antidsDNA. Aid in clinical-decision making? Lots of potential for monitoring tx response. @Rheumnow #ACR24 abs1642 #ACRbest https://t.co/C7ZNdvbIQ7